Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21714219 | 0.89 | CCNT1 (0.51) | CCNT1CDK9GPR119HTR6CYP3A4 | |
| SCHEMBL21714212 | 0.84 | HTR6 (0.48) | CCNT1CDK9GPR119HTR6CYP3A4 | |
| SCHEMBL21714258 | 0.83 | GPR119 (0.42) | GPR119HTR6CYP3A4MMP13 | |
| SCHEMBL23322330 | 0.79 | MET (0.47) | GPR119CYP3A4MMP13 | |
| SCHEMBL21714350 | 0.79 | GPR119 (0.41) | CCNT1CDK9GPR119HTR6MMP13 | |
| SCHEMBL17583115 | 0.78 | GPR119 (0.60) | GPR119HTR6CYP3A4MMP13 | |
| SCHEMBL21714463 | 0.78 | CCNT1 (0.52) | CCNT1CDK9GPR119 | |
| SCHEMBL28970123 | 0.76 | GPR119 (0.38) | KITGPR119HTR6CYP3A4 | |
| SCHEMBL10228635 | 0.75 | GPR119 (0.55) | GPR119HTR6CYP3A4 | |
| SCHEMBL6128795 | 0.75 | GPR119 (0.55) | GPR119HTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | claimed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | claimed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | CCNT1 2705/4885CDK9 1396/4885KIT 54/4885 |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | SHH, GLI1, SMO | CCNT1 2652/4885CDK9 1409/4885KIT 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.